ライフサイエンスコーパス: deep venous thrombosis

1 ceptives, and had no history to suggest past deep venous thrombosis).

2 ons, such as pulmonary embolism or recurrent deep venous thrombosis.

3 sis of pulmonary embolism or lower-extremity deep venous thrombosis.

4 enous ultrasonography of both legs showed no deep venous thrombosis.

5 t; in the placebo group, 1 patient developed deep venous thrombosis.

6 as 1.25 mm for pulmonary emboli and 5 mm for deep venous thrombosis.

7 provide recommendations to prevent in-flight deep venous thrombosis.

8 y protocol to identify or exclude concurrent deep venous thrombosis.

9 ous units, presence of fluid collection, and deep venous thrombosis.

10 nd a specificity of 100% for femoropopliteal deep venous thrombosis.

11 s) to determine the presence and location of deep venous thrombosis.

12 involvement, advanced immunosuppression, and deep venous thrombosis.

13 mbus, which was seen in 17% of patients with deep venous thrombosis.

14 etical cohorts of 60-year-old men with acute deep venous thrombosis.

15 reatment reduces mortality rates after acute deep venous thrombosis.

16 ight heparins may simplify the management of deep venous thrombosis.

17 t factor XIII Val34Leu is protective against deep venous thrombosis.

18 increased risk for venographically detected deep venous thrombosis.

19 antifibrin scintigraphy when used to detect deep venous thrombosis.

20 patients had supportive studies documenting deep venous thrombosis.

21 increase in the rate of lower limb proximal deep venous thrombosis.

22 drugs by the investigators; the patient had deep venous thrombosis.

23 ith malignancy after initiating treatment of deep venous thrombosis.

24 ular and femoral sites, and for diagnosis of deep venous thrombosis.

25 en of 45 patients (42.2%) were found to have deep venous thrombosis.

26 loodstream infections, and the prevalence of deep venous thrombosis.

27 after the computed tomography scan to detect deep venous thrombosis.

28 y embolisms, 11 (33.3%) were associated with deep venous thrombosis.

29 venous access, lower extremity itching, and deep venous thrombosis.

30 patients having both pulmonary embolism and deep venous thrombosis.

31 ions, including bladder neck contracture and deep venous thrombosis.

32 h acute ischemic infarct (23.3%), one with a deep venous thrombosis (1.4%), eight with multiple micro

33 rs), stroke (9 more per 10 000 woman-years), deep venous thrombosis (12 more per 10 000 woman-years),

34 .9%) with ischemic stroke, and 1 (0.1%) with deep venous thrombosis; 28 patients (2.4%) died for card

35 Deep venous thrombosis (6%-32%) and inferior vena cava t

36 sed stroke (11 more per 10 000 woman-years), deep venous thrombosis (7 more per 10 000 woman-years),

37 al, 51% of patients (145/284) had associated deep venous thrombosis, 91% (279/306) had cardiovascular

38 sistent in patients with pulmonary embolism, deep venous thrombosis, a body weight >/=100 kg, moderat

39 e coronavirus disease 2019 were screened for deep venous thrombosis after ICU admission with 102 dupl

40 Secondary outcomes included symptomatic deep venous thrombosis; all pulmonary embolisms; fatal p

41 h pulmonary embolism alone, 31 patients with deep venous thrombosis alone, and 58 patients with both.

42 There was no difference in incidence of deep venous thrombosis among different pharmacologic pro

43 Few studies have compared the incidence of deep venous thrombosis among ethnic groups.

44 gh well-established for suspected lower limb deep venous thrombosis, an algorithm combining a clinica

45 nt (0.8%) developed an asymptomatic proximal deep venous thrombosis and 7 patients (5.9%) developed d

46 ders have a very low incidence of idiopathic deep venous thrombosis and a very low relative risk for

47 vascular interventions for acute iliofemoral deep venous thrombosis and chronic iliofemoral venous ob

48 sleep disturbance, head drop, prevention of deep venous thrombosis and end-of-life issues.

49 f 122 [2.5%]) and without (23 of 844 [2.7%]) deep venous thrombosis and in the age- and sex-matched U

50 e risk of central venous catheter-associated deep venous thrombosis and its effect on thrombin genera

51 patients, infections in 4 of 8 patients, and deep venous thrombosis and neutropenia in one patient ea

52 o receive oral contraceptives, there was one deep venous thrombosis and one clotted graft; in the pla

53 Venous thromboembolism (VTE) comprising deep venous thrombosis and pulmonary embolism is a major

54 ong all 40 patients treated with MGDF, 1 had deep venous thrombosis and pulmonary embolism, and anoth

55 s thromboembolism (VTE), which includes both deep venous thrombosis and pulmonary embolism, is a comm

56 s to aid in the diagnosis of lower extremity deep venous thrombosis and pulmonary embolism.

57 o splenectomy; venous thromboembolism (VTE) (deep venous thrombosis and pulmonary embolus) after sple

58 ents developed thromboembolic complications (deep venous thrombosis and/or pulmonary emboli).

59 up, there were 1 death, 1 stroke, 2 cases of deep venous thrombosis, and 1 case of thrombosis in an a

60 Ten patients (50%) experienced deep venous thrombosis, and 1 eventually developed a maj

61 surgical site infection, pulmonary embolism, deep venous thrombosis, and death.

62 One patient had deep venous thrombosis, and one patient developed acute

63 ns due to medical care, respiratory failure, deep venous thrombosis, and sepsis.

64 transient neurologic ischemic attacks, four deep venous thrombosis, and two pulmonary emboli.

65 ldren and determining methods for diagnosing deep venous thrombosis associated with a catheter in the

66 It is critical to treat deep venous thrombosis at an early stage to avoid develo

67 s against central venous catheter-associated deep venous thrombosis at lower factor VIII activity and

68 s reliable for screening for lower extremity deep venous thrombosis at or above a concentration of 3,

69 or preventing mortality, pulmonary embolism, deep venous thrombosis, bleeding outcomes, or thrombocyt

70 , renal failure or insufficiency, pneumonia, deep venous thrombosis, bleeding, deep wound infection,

71 dimers were markedly higher in patients with deep venous thrombosis, both for maximum value and value

72 Risk for symptomatic deep venous thrombosis, but not risk for death or nonfat

73 Of the 176 patients, 35 (19.9%) had deep venous thrombosis by compression ultrasonography, i

74 heart failure, atrial fibrillation, stroke, deep venous thrombosis, cardiovascular death, and total

75 n after imaging diagnosis of the first three deep venous thrombosis cases was confirmed; therapeutic

76 the first cycle of therapy due to toxicity (deep venous thrombosis, chest palpitations).

77 , history of cancer, past medical history of deep venous thrombosis, coma, and high platelet count.

78 Prophylaxis against deep venous thrombosis consisted of venous compression s

79 atheter use is complicated by a high risk of deep venous thrombosis despite antithrombotic prophylaxi

80 rombosis, thus resulting in 38.7% with PE or deep venous thrombosis, despite 40% receiving prophylact

81 relevant central venous catheter-associated deep venous thrombosis developed in one of 27 children (

82 te risk reduction [ARR], 0.8%), asymptomatic deep venous thrombosis (DVT) (4 trials; relative risk [R

83 in 90 days, including pulmonary embolism and deep venous thrombosis (DVT) (above or below the knee).

84 ed plasma fibrinogen is associated with both deep venous thrombosis (DVT) and its complication, pulmo

85 f cerebrovascular events (CVA), a history of deep venous thrombosis (DVT) and pulmonary embolism (PE)

86 The mortality risks for patients with deep venous thrombosis (DVT) and pulmonary embolism (PE)

87 Deep venous thrombosis (DVT) and secondary pulmonary emb

88 CS National Trauma Data Bank for episodes of deep venous thrombosis (DVT) and/or pulmonary embolism (

89 All of the available diagnostic tests for deep venous thrombosis (DVT) have limitations for exclud

90 ophilia therapy, but the risk of CVC-related deep venous thrombosis (DVT) in hemophiliacs is not well

91 The second was to confirm the absence of deep venous thrombosis (DVT) in patients with bilateral

92 asis pathways that have been associated with deep venous thrombosis (DVT) in the general population a

93 Deep venous thrombosis (DVT) is a common problem with po

94 effect of lipid lowering on the incidence of deep venous thrombosis (DVT) is controversial.

95 Deep venous thrombosis (DVT) is one of the most common c

96 However, it is associated with rates of deep venous thrombosis (DVT) of approximately 38% to 55%

97 tandard anticoagulation for acute, occlusive deep venous thrombosis (DVT) of the proximal lower extre

98 terature, the diagnostic role of d-dimer for deep venous thrombosis (DVT) or pulmonary embolism (PE)

99 t permits scintigraphic detection of chronic deep venous thrombosis (DVT) or pulmonary embolism (PE)

100 Deep venous thrombosis (DVT) remains a common and seriou

101 Clinical assessment of suspected deep venous thrombosis (DVT) should be based on systemat

102 The incidence of deep venous thrombosis (DVT) was 6.2% (n= 132), with sig

103 The presence of pulmonary embolism or deep venous thrombosis (DVT) was recorded for all patien

104 ctive evaluation of patients with cancer and deep venous thrombosis (DVT) who underwent FDG-PET and e

105 We also determined the association of deep venous thrombosis (DVT) with the presence of an IVC

106 ultrasonography cannot rule out symptomatic deep venous thrombosis (DVT) without further testing, su

107 The rates of deep venous thrombosis (DVT), pulmonary embolism, and VT

108 urinary tract infection, pneumonia, sepsis, deep venous thrombosis (DVT), pulmonary embolism, venous

109 pool contrast agent, ferumoxytol, to depict deep venous thrombosis (DVT).

110 reated with any type of chemotherapy develop deep venous thrombosis (DVT).

111 ) is a common and burdensome complication of deep venous thrombosis (DVT).

112 is sensitive but not specific for diagnosing deep venous thrombosis (DVT).

113 aumatic PE might be different from those for deep venous thrombosis (DVT).

114 lant therapy from cancer patients with acute deep venous thrombosis (DVT; DVT + cancer group, n = 32)

115 ) disease, either pulmonary embolism (PE) or deep-venous thrombosis (DVT), at time of presentation; t

116 Standardised incidence ratios (SIR) of deep-venous thrombosis (DVT), pulmonary embolism, and ar

117 to four time after the original diagnosis of deep venous thrombosis; eight also underwent confirmator

118 dabigatran, anticoagulation in patients with deep venous thrombosis, estimation of warfarin dose, use

119 patients with PR3-ANCA, nine had documented deep venous thrombosis events, five of whom were positiv

120 This issue provides a clinical overview of deep venous thrombosis, focusing on prevention, diagnosi

121 al fibrillation (14 of 44 patients, 32%) and deep venous thrombosis (four of 44 patients, 9%).

122 These criteria may help distinguish acute deep venous thrombosis from the residual changes of prev

123 Grade 3 deep venous thrombosis, grade 3 back pain, and grade 3 v

124 Patients found to have deep venous thrombosis had no difference in time to intu

125 ny as 50% of children with catheters develop deep venous thrombosis; however, most events are clinica

126 ns, with 12 cases (16.7%) of lower extremity deep venous thrombosis identified.

127 utpatients suspected of having first-episode deep venous thrombosis if results of simplified compress

128 Prolonged air leak in 141, deep venous thrombosis in 64, Atrial fibrillation in 42,

129 Autopsy revealed deep venous thrombosis in 7 of 12 patients (58%) in whom

130 n against central venous catheter-associated deep venous thrombosis in critically ill children.

131 The prevalence of deep venous thrombosis in patients with advanced cancer

132 is available about the prospective risk for deep venous thrombosis in specific high-risk clinical se

133 tation was not significantly associated with deep venous thrombosis in subgroups of patients receivin

134 vein compression accurately detects proximal deep venous thrombosis in symptomatic outpatients.

135 n is not a significant risk factor for acute deep venous thrombosis in this group of patients.

136 f 116 patients had pulmonary embolism and/or deep venous thrombosis, including 27 patients with pulmo

137 Deep venous valves are frequent sites of deep venous thrombosis initiation.

138 ining diagnostic imaging studies to rule out deep venous thrombosis is exacerbated by increased susce

139 Lower extremity deep venous thrombosis is prevalent in coronavirus disea

140 for thrombolytic agents for less symptomatic deep venous thrombosis is undefined.

141 Deep venous thrombosis is very common in critically ill

142 sm (VTE), composed of pulmonary embolism and deep venous thrombosis, is a significant cause of matern

143 The causal relationship that deep venous thrombosis leads to impairment in lung funct

144 of CRT include pulmonary embolism, recurrent deep venous thrombosis, loss of central venous access, a

145 In a rat deep venous thrombosis model used to assess antithrombot

146 y bacterial or fungal infection (n = 7), and deep venous thrombosis (n = 1).

147 Other than deep venous thrombosis noted in some patients, no other

148 a, venous stenosis, right heart failure, and deep venous thrombosis occurred in 10, 7, 4, and 4 patie

149 nfidence interval 1.6-10) but not upper-limb deep venous thrombosis (odds ratio 0.6; 95% confidence i

150 ry embolism risk was increased by lower-limb deep venous thrombosis (odds ratio 4.0; 95% confidence i

151 ient died of fluid overload, and one died of deep venous thrombosis of calf veins with pulmonary thro

152 dren with central venous catheter-associated deep venous thrombosis on ultrasonography in the enoxapa

153 ortion of central venous catheter-associated deep venous thrombosis on ultrasonography in the usual c

154 d graft; in the placebo group, there was one deep venous thrombosis, one ocular thrombosis, one super

155 Six patients presented with only a deep venous thrombosis or a pulmonary embolism; 1 patien

156 Documented VTE (deep venous thrombosis or pulmonary embolism) and unprov

157 r evolocumab reduces the risk of VTE events (deep venous thrombosis or pulmonary embolism).

158 ity, and 10 (20%) had thromboembolic events (deep venous thrombosis or pulmonary embolism).

159 patients who have been given a diagnosis of deep venous thrombosis or pulmonary embolism.

160 Documented deep venous thrombosis or pulmonary embolism.

161 om 1982 to August 1994 for the occurrence of deep venous thrombosis or pulmonary embolism.

162 est requiring cardiopulmonary resuscitation, deep venous thrombosis or thrombophlebitis, coma lasting

163 2.08 [95% CI, 1.41 to 3.06]); postoperative deep venous thrombosis (OR, 1.96 [95% CI, 1.18 to 3.26])

164 re the presence of hypercoagulability, prior deep venous thrombosis, or a cavopulmonary anastomosis.

165 a included recurrent varicose veins, current deep venous thrombosis, or serious arterial disease.

166 venous line (P < .001), and prior PE and/or deep venous thrombosis (P < .001), were found to be sign

167 actic regimen was not related to presence of deep venous thrombosis (p = 0.35).

168 upper gastrointestinal bleeding, sepsis, or deep venous thrombosis (P=0.05).

169 e range, 638-3,735 ng/mL] for no evidence of deep venous thrombosis; p < 0.0001).

170 ths of treatment, there was no recurrence of deep venous thrombosis, partial recanalization within af

171 on (APL), postoperative pulmonary embolus or deep venous thrombosis (PEDVT), foreign body left during

172 itors can prevent 4 instances of symptomatic deep venous thrombosis per 1000 treated patients (CI, 3

173 The annual incidence of idiopathic deep venous thrombosis per 1000000 persons older than 18

174 y analyses by varying in-hospital mortality, deep venous thrombosis prevalence, and ultrasound accura

175 Bedside consideration improved on the use of deep venous thrombosis prophylaxis (p < .05), stress ulc

176 Fifty-two patients (44%) were treated with deep venous thrombosis prophylaxis on postoperative day

177 embolic disease in pancreatic cancer include deep venous thrombosis, pulmonary embolism, disseminated

178 urinary tract infection, pneumonia, sepsis, deep venous thrombosis, pulmonary embolism, venous throm

179 The primary outcome was VTE (deep venous thrombosis/pulmonary embolism) within 1 year

180 001), other diseases of the vascular system (deep venous thrombosis/pulmonary embolism, peripheral va

181 rtainty) but resulted in a small increase in deep venous thrombosis (relative risk, 2.01; 95% CI, 1.0

182 sm has decreased over time, the incidence of deep venous thrombosis remains unchanged, indicating the

183 detecting underlying cancer in patients with deep venous thrombosis remains unknown.

184 for thromboembolic complications, including deep venous thrombosis, renal vein thrombosis, and pulmo

185 not increase the risk of lower limb proximal deep venous thrombosis (RR 0.97, 95% CI 0.72-1.29, P = 0

186 t common complication was cannula-associated deep venous thrombosis (six patients, 23.1%).

187 For idiopathic deep venous thrombosis, standardized age- and sex-adjust

188 (PTS), a substantial number of patients with deep venous thrombosis still develop PTS.

189 sible alternative outcome measure for future deep venous thrombosis studies.

190 Megestrol acetate had a higher rate of deep venous thrombosis than dexamethasone (5% v 1%; P =.

191 , central nervous system manifestations, and deep venous thrombosis that impacts systemic and local i

192 hildren are at increased risk for developing deep venous thrombosis, there are few pediatric studies

193 d heparin and mortality, pulmonary embolism, deep venous thrombosis, thrombocytopenia, and bleeding o

194 Among 89 patients with deep venous thrombosis, thrombosis was bilateral in 26,

195 Epidural catheters may directly prevent deep venous thrombosis through sympathetic blockade, res

196 or acute limb ischemia, or clinically silent deep venous thrombosis, through hospital discharge or 28

197 tive results at CT pulmonary angiography had deep venous thrombosis, thus resulting in 38.7% with PE

198 duce thrombus burden in the setting of acute deep venous thrombosis to prevent both short- and long-t

199 osis, pulmonary embolism, clinically evident deep venous thrombosis, type 1 myocardial infarction, is

200 been evaluated for suspected upper extremity deep venous thrombosis (UEDVT).

201 In patients with deep venous thrombosis, use of elastic compression stock

202 nge, 3,176-30,770 ng/mL] for lower extremity deep venous thrombosis vs 2,087 ng/mL [interquartile ran

203 ratio of central venous catheter-associated deep venous thrombosis was 0.55 (95% credible interval,

204 vs. 95.8 per 100,000), and the incidence of deep venous thrombosis was 3 times higher than that of p

205 The absolute incidence of deep venous thrombosis was 31% (95% CI, 15% to 47%) in p

206 The risk of deep venous thrombosis was assessed in the two randomize

207 Venographically diagnosed postoperative deep venous thrombosis was correlated with factor V geno

208 Deep venous thrombosis was diagnosed in 142 patients (14

209 Deep venous thrombosis was documented in 9 patients, and

210 at a median of 34 months after diagnosis of deep venous thrombosis was obtained through hospital cha

211 Deep venous thrombosis was seen in isolation in 14 patie

212 ad venous ultrasonography because idiopathic deep venous thrombosis was suspected.

213 s, (mainly pulmonary embolism and lower limb deep venous thrombosis) was lower after vaccination.

214 patients with the first episode of proximal deep venous thrombosis were randomized to wear either th

215 that there was no difference in the risk of deep venous thrombosis when the femoral site was compare

216 as diagnosed in none of the 56 patients with deep venous thrombosis who did not have findings on the

217 We present the case of a man bedridden by deep venous thrombosis who was given intraclot instillat

218 In randomized trial arms, the rate of deep venous thrombosis with additional pharmacological t

219 ratios of central venous catheter-associated deep venous thrombosis with prophylaxis with enoxaparin

220 ve lipomas, benign and malignant tumors, and deep venous thrombosis with pulmonary embolism.

221 There was one case of major deep venous thrombosis with pulmonary embolism.

222 h included 3.9% pulmonary embolism and 16.3% deep venous thrombosis, with 1.5% of patients having bot

223 small absolute risk reduction in symptomatic deep venous thrombosis without increasing bleeding.